Findings from a planned sub-analysis of clinical trial data comparing treatment options for renal cell carcinoma patients (RCC) with sacromatoid history were presented at the 2019 American Society…
The US Food and Drug Administration (FDA) has approved the immunotherapy avelumab in combination with the tyrosine kinase inhibitor axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The…
According to the Associated Press’ search of a U.S. government database, six of the eight currently registered clinical trials studying deep brain stimulation (DBS) for addiction treatment are…
F. Perry Wilson, MD, MSCE, shares insights from a review of recent study results published in the New England Journal of Medicine examining duty-hours rules at 63 residency…
New data shows that cabozantinib, a drug already approved in the treatment of clear cell renal cell carcinoma (ccRCC), elicited promising results in patients with less common non-clear…
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center in Boston, Massachusetts presented results from the KEYNOTE-427 study at the Genitourinary Cancers…
A phase 1b study showed pembrolizumab and axitinib extended both overall survival (OS) and progression-free survival (PFS) in patients with previously untreated mRCC. “The risk of death was…
Historically, high-sensitivity diagnostic testing for many common diseases consisted of sending samples to an offsite laboratory and potentially waiting hours or days before results were attained and shared…
A new technique makes cancerous tumors glow, which in turn makes it easier to fully remove them during surgery. Employing nanotechnology designed to administer small-molecule drugs, physician researchers…
A research team from Brazil evaluated the link between anxiety and depression — nonmotor symptoms of Parkinson’s disease (PD) — and freezing of gait. They found that roughly…
